Is Inspire Medical Systems, Inc. (INSP) Undervalued? Valuation & Fair Price
At $71.30, the frameworks are split on Inspire Medical Systems, Inc. today — Warren Buffett and Peter Lynch rate it Buy, Phil Town (Rule #1) rates it Avoid, and Benjamin Graham rates it Hold. Each model calculates its own fair value and margin of safety; create a free account to see the exact buy price behind every verdict.
Inspire Medical Systems, Inc.
INSPHealthcare · Medical - Devices · NYSE
$71.30
P/E 12.5×
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.
Investor scorecard
How the four investors rate Inspire Medical Systems, Inc.
A split decision across the frameworks
Investor model analysis
Details lockedAt $71.30, 2 of 4 frameworks say Buy
Intrinsic Value (DCF)
Warren Buffett's valuation model · select an investor above to switch
Intrinsic Value
Locked — upgrade to viewBuy Below
Locked — upgrade to viewStrong Buy
Locked — upgrade to viewMargin of Safety
Locked — upgrade to viewUnlock buy targets with a free account
Get startedCreate a free account to see buy targets, full checklists & risk analysis Get started
Insider & congress activity
Are insiders buying INSP?
Over recent SEC Form 4 filings, INSP insiders bought $804 and sold $2.0M of stock across 14 open-market trades. Insiders sell for many reasons, but they buy for one.
| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| Kelly Jason PSee Remarks | Sell | 963 | $57K | Aug 7, 2026 |
| Rondoni JohnSee Remarks | Sell | 2,641 | $114K | May 15, 2026 |
| Rondoni JohnSee Remarks | Sell | 700 | $30K | May 14, 2026 |
| McCormick Shawndirector | Sell | 696 | $32K | May 8, 2026 |
| Rondoni JohnSee Remarks | Sell | 109 | $11K | Jan 9, 2026 |
Members of Congress have also reported 1 trade in INSP. See the full insider & congress timeline.
Source: SEC Form 4 filings. Open-market buys & sells only. Not investment advice.
See the interactive insider chart & every tradeScenario analysis
Bear, base & bull
Three growth assumptions, three fair values — and where today's price lands
What's working
Key strengths
Identified by Buffett framework analysis
Company financials
5-Year Financials
Income statement highlights — annual, USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $912M | $803M | $625M | $408M | $233M |
| Rev. Growth | +13.6% | +28.5% | +53.2% | +74.7% | — |
| Net Income | $145M | $54M | -$21M | -$45M | -$42M |
| Net Margin | 15.9% | 6.7% | -3.4% | -11.0% | -18.0% |
| EPS (Diluted) | $4.95 | $1.80 | $-0.72 | $-1.60 | $-1.54 |
| Free Cash Flow | Locked — upgrade to view | Locked — upgrade to view | Locked — upgrade to view | Locked — upgrade to view | Locked — upgrade to view |
Full analysis included
See the complete picture for INSP
Exact buy targets, margin of safety, detailed investor checklists, and risk breakdown — all frameworks, all numbers.
Free: 3 analyses/month · Pay per stock: $4.99 · Pro: $19.99/mo
More Healthcare stocks
Educational Use Only · Not Financial Advice
Analysis, scores, valuations, and buy zones are derived from publicly documented investor frameworks (Buffett, Lynch, Benjamin Graham, Phil Town) for learning purposes only. They are not recommendations from licensed financial advisors. Past performance does not guarantee future results. Prices may be delayed up to 15 minutes. Always conduct your own research before making any investment decisions.